Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has been given a consensus recommendation of “Hold” by the twelve research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $8.17.

Several research analysts have recently issued reports on ZYNE shares. Jefferies Group LLC restated a “buy” rating and set a $32.00 price objective on shares of Zynerba Pharmaceuticals in a report on Thursday, May 25th. Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 30th. Maxim Group restated a “buy” rating and set a $32.00 price objective on shares of Zynerba Pharmaceuticals in a report on Thursday, June 8th. Cantor Fitzgerald set a $28.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, June 8th. Finally, Roth Capital set a $30.00 price objective on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 10th.

TRADEMARK VIOLATION NOTICE: “Zynerba Pharmaceuticals, Inc. (ZYNE) Receives $8.17 Consensus Target Price from Analysts” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/19/zynerba-pharmaceuticals-inc-zyne-receives-8-17-consensus-target-price-from-analysts.html.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 1.87% during trading on Friday, reaching $6.30. 182,001 shares of the company’s stock were exchanged. Zynerba Pharmaceuticals has a 1-year low of $6.10 and a 1-year high of $23.57. The company’s 50-day moving average is $6.28 and its 200-day moving average is $8.47. The company’s market capitalization is $83.52 million.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Equities research analysts expect that Zynerba Pharmaceuticals will post ($2.42) earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors acquired a new stake in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at about $110,000. The Manufacturers Life Insurance Company acquired a new position in Zynerba Pharmaceuticals in the second quarter valued at about $158,000. FNY Managed Accounts LLC acquired a new position in Zynerba Pharmaceuticals in the first quarter valued at about $180,000. SG Americas Securities LLC acquired a new position in Zynerba Pharmaceuticals in the first quarter valued at about $188,000. Finally, New York State Common Retirement Fund acquired a new position in Zynerba Pharmaceuticals in the second quarter valued at about $207,000. Institutional investors and hedge funds own 34.32% of the company’s stock.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Stock Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.